Non-profit research partnership the Structural Genomics Consortium adds Pfizer and Eli Lilly to its consortium as it closes a funding round worth nearly $50m.

The Structural Genomics Consortium (SGC), a public-private partnership which carries out research relevant for drug discovery, secured $48.9m in funding last Wednesday from a range of investors.

Multinational pharmaceutical corporations Eli Lilly, through its Eli Lilly Canada division, and Pfizer became the newest members of the consortium making up the SGC, joining existing investors including the Novartis Research Foundation, a division of pharmaceutical corporation Novartis, healthcare conglomerate GlaxoSmithKline (GSK), federal agency the Canadian Institutes for Health Research, government ministry the Ontario…